Locanabio Announces Presentation of Preclinical Data Demonstrating an Improved Vectorized snRNA Platform with Applications in Exon Skipping for the Potential Treatment of Duchenne Muscular Dystrophy (DMD) at the 28th Annual Congress of the World Muscle Society (WMS2023)
06 oct. 2023 08h00 HE
|
Locanabio, Inc.
Locanabio presents preclinical data on improved vectorized snRNA platform for exon skipping for the potential treatment of DMD at WMS2023
Locanabio Announces Participation in Chardan’s 7th Annual Genetic Medicines Conference
25 sept. 2023 16h01 HE
|
Locanabio, Inc.
SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative...
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
16 mai 2023 06h00 HE
|
Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
Locanabio Announces Equity Investment from CureDuchenne Ventures to Support Development of snRNA Exon Skipping Approach for Duchenne Muscular Dystrophy (DMD)
15 mai 2023 08h00 HE
|
Locanabio, Inc.
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative...
Locanabio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
02 mai 2023 16h30 HE
|
Locanabio, Inc.
Locanabio to report preclinical data from snRNA exon skipping program in DMD and Cas13d-mediated C9orf72 ALS program SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines...
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
20 avr. 2023 08h00 HE
|
Locanabio, Inc.
Preclinical data from LBIO-115 exon 51 program demonstrate superior levels of exon-skipping that result in high levels of dystrophin restoration Data presented at the CureDuchenne FUTURES 2023...